Defiance Daily Target 2X Long LLY ETF

Indie Asset Partners LLC increased holdings in Eli Lilly

Eli Lilly Foundation Sells Shares of Eli Lilly

Eli Lilly Annual Meeting Fails to Pass Governance Change Proposals

Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion

Hims &amp; Hers Health Launches Multiple FDA-Approved GLP-1 Drugs

Herbst Group LLC Purchases 1,925 Shares of Eli Lilly in Q4

Eli Lilly Requests UK to Increase Drug Prices in Exchange for Investment

Eli Lilly Announces Plan to Invest $3 Billion Over Decade to Expand Supply Chain in China

WHO Foundation and Eli Lilly Collaborate to Strengthen Obesity Care Systems

Eli Lilly's Clinical Trial Shows Significant Improvement in Psoriasis and Weight Loss with Zepbound and Taltz Combination

Eli Lilly and LiLai Pharmaceutical Co-develop Tolerability Therapy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

LLYX

ELIL

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

PUBT

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

ELIS

Eli Lilly (LLY) has emerged as a leader in the obesity drug market with its GLP-1 based products, Mounjaro and Zepbound, significantly boosting its stock. However, concerns about policy uncertainties and elevated expectations suggest that the market may have already priced in much of the growth potential. While demand for obesity treatments remains strong, potential risks could lead to volatility, prompting a neutral stance on LLY.

Tip Ranks

Direxion Daily LLY Bear 1X Shares

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

LABU

Eli Lilly And Company (LLY) is advancing its clinical trial for LY4005130, a new drug for severe alopecia areata. The Phase 2 study aims to evaluate the drug's efficacy and safety over one year, comparing it to a placebo. This trial is significant for Lilly's expansion into immunology and dermatology, potentially enhancing its growth profile. The study is currently recruiting participants, with updates available on the ClinicalTrials portal. A successful outcome could strengthen Lilly's position in the market, while setbacks may impact investor sentiment regarding its non-diabetes pipeline.

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VG Health

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Johnson & Johnson

Abbvie

Eli Lilly’s New Alopecia Drug Trial Moves Forward, Expanding Its Immunology Pipeline

LLYZ

Eli Lilly and Company (NYSE: LLY) and UNICEF USA have launched a six-year initiative on May 14, 2026, in New York and Indianapolis to enhance prevention and care for non-communicable diseases in children residing in low- and middle-income countries. This partnership seeks to address the pressing issue by leveraging resources and expertise, with the goal of significantly impacting the lives of children in need.

Unusual Whales

Defiance Daily Target 2X Short LLY ETF

Lilly and UNICEF collaborate to give millions of children a healthier start

Eli Lilly has partnered with Caitlin Clark’s foundation to open three multisport community courts in Indianapolis, including two at public schools and one in a park. This initiative is part of Lilly's 150th anniversary celebrations, with the courts designed for basketball, soccer, and futsal. The project involves Musco Lighting and aims to enhance community access to sports facilities. Lilly's campaign, '150 Years of Everything Else,' promotes its brand through various media.

Fiercepharma

Lilly allies with Caitlin Clark for Indianapolis sports courts

Stonebridge Financial Group LLC MO acquired 1,397 shares of Eli Lilly and Company (NYSE: LLY) in Q4, valued at approximately $1.5 million, making it the 18th largest position in their portfolio. Other investors, including 10Elms LLP and M.E. Allison & CO. Inc., also adjusted their stakes in Eli Lilly. The company continues to receive positive sentiment due to its obesity drugs and recent developments, despite facing competitive pressures and regulatory challenges.

Market Beat

Novo Nordisk AS

Hims & Hers Health

Kailera Therapeutics

1,397 Shares in Eli Lilly and Company $LLY Purchased by Stonebridge Financial Group LLC MO

Eli Lilly's recent studies reveal that patients can maintain significant weight loss after switching from higher-dose injectable therapies to Foundayo or lower-dose Zepbound. The SURMOUNT-MAINTAIN trial showed that both Zepbound and a reduced 5 mg dose met primary goals, with patients preserving weight loss. The ATTAIN-MAINTAIN study indicated that those switching to Foundayo also maintained weight reduction. Eli Lilly's stock rose 1.52% to $1,004.90, with Mounjaro and Zepbound revenues increasing significantly. Overall, Eli Lilly has gained 6.7% over the past month, despite a 7% year-to-date decline.

benzinga_article

S&P 500

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News

StockTitan

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News

The U.S. Supreme Court has rejected Eli Lilly's appeal regarding a $194 million whistleblower judgment for underpaying Medicaid rebates by misreporting drug pricing. The decision upholds the federal False Claims Act, allowing private individuals to sue on behalf of the government. Eli Lilly's stock fell 1.64% to $988.42 following the ruling, with the company arguing that the whistleblower's claims were unfounded and that its pricing practices were industry-standard.

Fidelity

Ondas

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

RHHVF

Roche has received European CE Mark approval for its Elecsys pTau217 Alzheimer's blood test, developed in collaboration with Eli Lilly. This test aims to detect amyloid pathology earlier in patients showing cognitive decline, potentially reducing reliance on invasive procedures. The approval is based on studies involving early-stage Alzheimer's patients, and Roche plans to expand the test's availability across Europe and potentially the U.S. later this year. Eli Lilly's stock is currently trading at approximately $976 per share, reflecting a 2.8% gain over the past month.

ROCHE HOLDINGS AG

Roche

Biogen

Taiwan Semiconductor

Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Defiance Daily Target 2X Long LLY ETF(LLYX.US)

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Eli Lilly’s New Alopecia Drug Trial Moves Forward, Expanding Its Immunology Pipeline

Lilly and UNICEF collaborate to give millions of children a healthier start

Lilly allies with Caitlin Clark for Indianapolis sports courts